Semaglutide reduces kidney disease events, cardiovascular outcomes, and all-cause mortality in type 2 diabetes patients with chronic kidney disease, per FLOW trial results.
In a groundbreaking study, semaglutide has been found to significantly reduce kidney disease events, cardiovascular outcomes, and all-cause mortality in patients with type 2 diabetes and chronic kidney disease. The FLOW trial, presented at the 61st ERA Congress, involved 3,533 patients and showed that semaglutide, a GLP-1 receptor agonist, reduced the primary composite endpoint by 24% compared with placebo. The trial results were published in the New England Journal of Medicine.
May 24, 2024
5 Articles